Symphony finds Rx hike from Medicaid claims

Share this article:
Symphony finds Rx hike from Medicaid claims
Don Otterbein

The Affordable Care Act has spurred double-digit increases in demand for pharmaceuticals, new data suggest. Prescription claims for Medicaid patients increased in January by 10% and in February by 14% over the same periods last year.

The study, by market research firm Symphony Health Solutions, links the three million or so who have newly signed up for Medicaid with the upturn. (Enrollment in private insurance under the ACA has reached 7.5 million, the Obama administration said, although that total did not include Medicaid enrollment.)

“Even with Medicaid expansion less than three months old, we're starting to see notable increases in Medicaid prescription claims,” said Don Otterbein, SVP marketing and product management, Symphony Health Solutions. “We expect this trend to continue.”

Symphony said the Medicaid data are a combination of third-party Medicaid and state-run Medicaid data from its managed care research product, which utilizes claims data from more than 42,000 unique retail pharmacies.

The Wall Street Journal, citing CMS stats, reported that about 61 million people were on Medicaid as of the end of February, vs. 58 million from a period of July to September 2013—an increase of three million enrollees since the start of the health law's open enrollment period October 1.

The study also uncovered that average out-of-pocket cost for contraceptives has dropped more than 58% since 2012. That data come from a look at commercial payers, female patients and the drug class for contraceptive agents.

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.